Abstract 23P
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, robust biomarkers precisely predicting treatment response have not yet been discovered. We aimed to evaluate tumor DNA methylation signatures as a potential new biomarker for ICI response.
Methods
Patients with non-small cell lung cancer (NSCLC) receiving ICIs at two independent tertiary care centres were retrospectively identified. DNA methylation profiles of tumor tissue FFPE specimen before initiation of ICI were analysed by Infinium Methylation EPIC microarrays and bioinformatically correlated with radiological response. Responders were defined as patients with complete remission or partial remission at first restaging. Response assessment was performed by board-certified radiologist according to iRECIST v1.1.
Results
In this preliminary analysis, a total of 95 patient samples (median age: 67 years [range: 36-89 years], 53 male, 42 female, 75 adenocarcinoma, 20 squamous cell carcinoma) were included. Supervised clustering according to ICI response revealed three distinct clusters (p<0.001). Cluster 1 included only ICI non-responders (29/29), while the majority of Cluster 3 consisted of responders (11/17). In further analysis according to histological subtype, the 3 clusters were also significantly associated with ICI response in the subgroup of adenocarcinoma as 39/41 (95.1%) in Cluster 1 were non-responders and 10/10 (100%) in Cluster 3 were responders (p<0.001). In squamous cell carcinoma, only 2 methylation clusters were evident. Cluster 1 with only non-responders (14/14) and Cluster 2 with mainly responders (5/6; p<0.001).
Conclusions
Tumor tissue methylation profiling may serve as a promising biomarker to predict ICI treatment response in NSCLC patients.
Legal entity responsible for the study
The authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
J. Furtner: Financial Interests, Personal, Invited Speaker: Seagen, Novartis, Sanova; Financial Interests, Personal, Advisory Board: Servier. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, CeCaVa, Seagen, Alexion, Servier; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche; Non-Financial Interests, Personal, Leadership Role, Board Member: European Association of Neuro-Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract